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Abstract: The idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group 
of chronic disorders that include dermatomyositis (DM), polymyositis (PM), sporadic 
inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM). They 
represent distinct pathological entities that, most often, share predominant inflammation in 
muscle tissue. Many of the immunopathogenic processes behind the IIM remain poorly 
understood, but the crucial role of cytokines as essential regulators of the intramuscular 
build-up of inflammation is undisputed. This review describes the extensive cytokine 
network within IIM muscle, characterized by strong expression of Tumor Necrosis Factors 
(TNFα, LTβ, BAFF), Interferons (IFNα/β/γ), Interleukins (IL-1/6/12/15/18/23) and 
Chemokines (CXCL9/10/11/13, CCL2/3/4/8/19/21). Current therapeutic strategies and the 
exploration of potential disease modifying agents based on manipulation of the cytokine 
network are provided. Reported responses to anti-TNFα treatment in IIM are conflicting 
and new onset DM/PM has been described after administration of anti-TNFα agents to 
treat other diseases, pointing to the complex effects of TNFα neutralization. Treatment 
with anti-IFNα has been shown to suppress the IFN type 1 gene signature in DM/PM 
patients and improve muscle strength. Beneficial effects of anti-IL-1 and anti-IL-6 therapy 
have also been reported. Cytokine profiling in IIM aids the development of therapeutic 
strategies and provides approaches to subtype patients for treatment outcome prediction. 
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1. Introduction 
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune muscle 
disorders that include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis 
(IBM), and necrotizing autoimmune myopathy (NAM) [1]. The different subcategories of patients can 
be identified by examining the combination of clinical, histological and imaging features. DM can be 
present in children and adults, and is most often associated with subacute onset of proximal muscle 
weakness and characteristic skin manifestations. Skin involvement usually manifests with Gottron’s 
papules, the heliotrope eruption and mechanic’s hands. An increased risk of internal malignancies and 
interstitial lung disease (ILD) is associated with DM, and cardiac involvement with histologic evidence 
of inflammatory alterations is also described. PM presents more commonly in adults with subacute 
onset of symmetrical proximal muscle weakness. IBM is diagnosed most often in patients over  
50 years of age. In most cases IBM is characterized by slowly progressive proximal and distal muscle 
weakness. A rare form of IIM is NAM, which presents as acute or subacute symmetrical proximal 
muscle weakness that develops after statin-use. As in DM, malignancies, ILD and cardiac involvement 
have also been reported. The different IIM subgroups present with distinct myopathological features. 
In DM, membrane attack complexes form on blood vessel endothelia, causing capillary loss and 
muscle ischaemia. In PM/IBM, nonnecrotic muscle fibers are invaded by autoaggressive CD8+ T-cells. 
The perforins and granzymes, they release, result in cytotoxic necrosis of the fibers [2]. In IBM, the 
inflammatory process is accompanied by degenerative phenomena and accumulation of abnormal 
protein aggregates inside the muscle fibers [3]. In NAM muscle tissue, inflammation is relatively rare 
and muscle fiber necrosis is the most prominent feature [4]. 
The chronic inflammation associated with the IIM is tightly regulated by cytokine expression. 
Cytokines are small proteins that, through their secretion, can shape immune cell function from a 
distance. The ultimate result is dependent not only upon cytokine concentration, but also on the local 
environment and the interactions with other cytokines and with non-immune cells. The sources of 
cytokines in human muscle tissues can be varied. Firstly, tissue-infiltrating immune cells are a rich 
source of cytokines, regulating each other’s activities and perpetuating the inflammatory response. 
Secondly, the muscle tissue constituents themselves can produce cytokines. It is well known that the 
interaction of muscle cells with immune cells can initiate and perpetuate immune responses in muscle 
tissue [5]. Muscle cells in culture constitutively express cytokines and can be stimulated to secrete  
an additional spectrum of pro-inflammatory cytokines, allowing them to participate to the immune 
reactions [6,7]. The blood vessel endothelium can also produce or present cytokines, allowing 
circulating responsive immune cells to find their way to tissue inflammation sites. 
In this review, we describe the role of cytokines in the immune cell infiltration in IIM, and 
summarize common and emerging therapeutic approaches that display potential for the manipulation 
of cytokine networks in patients. 
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2. Roles of Cytokines in the Build-up of Inflammation in the IIM 
In IIM; infiltrating macrophages; T-cells; B-cells; and dendritic cells (DC) are most often present  
in the affected skeletal muscles. These cells might contribute to a further inflammatory stimulus by 
perpetuated production of cytokines; and regulating the immune reactions in a profound way by 
recruiting; activating and shaping the activities of these tissue-infiltrating inflammatory cells. 
2.1. Innate Immunity Activation 
While autoimmunity is perceived to be mostly mediated by an adaptive immune response raised 
against self antigens, inappropriate activation of innate immune mechanisms has been shown to 
contribute substantially to the disease process. Innate or native immunity is the earliest line of host 
defense. In stressed cells undergoing necrosis, damage-associated molecular patterns (DAMPs or 
alarmins) that act as endogenous danger signals, are delivered to Toll-Like Receptors (TLR), leading 
to induction of nuclear factor κB (NF-κB) and its respective downstream pro-inflammatory cytokines 
including interferon (IFN) α/β, tumor necrosis factor (TNF) α, interleukin (IL)-1, IL-12 and IFNγ [8]. 
Innate immune reactions are mediated by phagocytic cells (neutrophils, macrophages, eosinophils), 
natural killer (NK) cells, the complement system, and the associated cytokines. 
Many elements point to activated innate immunity in the IIM in general, and in DM in particular. 
TLR upregulation is strongly associated with the IIM. Recently in IBM, the “alarmin” High mobility 
group box-1 (HMGB1), a mediator of the innate immune response, has been demonstrated to play a 
crucial role in the inflammatory and degenerative network [9]. In DM, the attack on the vascular 
endothelium originates from complement-mediated humoral reactions and results in muscle and skin 
injury [10]. The type 1 IFN pathway is strongly associated with DM pathogenesis, and is upregulated 
in muscle, skin and in peripheral blood [11] and correlates with disease activity [12]. The cytokines  
IL-2 and IL-15, which share a receptor, have also been associated with innate immune reactions. IL-15 
is involved in NK-cell development and proliferation, and is constitutively expressed in many cell 
types. In addition, IL-15 is an inducer of myocyte differentiation [13]. Barely expressed in healthy 
muscle, in DM/PM patients IL-15 is secreted by muscle cells through interaction with infiltrating  
T-cells [14]. In IIM tissue, IL-15 is expressed by infiltrating macrophages but not by T-cells [15]. 
Induction has been observed in both the muscle tissue and in serum of IIM patients, with IL-15 serum 
levels being significantly higher in adult DM than in PM [16]. IFNα and IL-2 were found to be  
7.5-fold and five-fold increased in DM/PM sera respectively compared to healthy controls [17]. 
Innate and adaptive immunity are not separate entities, but are tightly connected through the  
activities of DC. DC are professional antigen-presenting cells divided into the more common myeloid 
DC and the IFNα-producing plasmacytoid DC. DC prime and activate naïve T-cells. Both myeloid  
and plasmacytoid, and immature and mature DC are present in IIM muscle [18] and in IBM,  
nonnecrotic muscle fibers are invaded by myeloid DC [19]. The cellular infiltrates in anti-HMG-CoA 
reductase-associated myopathy also contain DC [20]. 
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2.2. Recruitment of Immune Cells 
In healthy skeletal muscle, small numbers of resident immune cells are present that perform normal 
tissue immune surveillance activities. In chronic inflammatory muscle diseases however, mechanisms 
are activated that lead to massive extravasation of immune cells from the circulation to muscle tissue 
inflammatory sites. This is accomplished by the tagging of the local blood vessel endothelium with 
factors that retain responsive immune cells. Adhesion molecules and cytokines are upregulated, 
allowing the circulating mononuclear cells to attach and subsequently transmigrate through the blood 
vessel wall into the tissue. Matrix-metalloproteinases facilitate the migration of cells on their way to 
their targets [21]. 
Various chemotactic cytokines termed chemokines are specialized for recruiting mostly monocytes. 
An important class are the Monocyte Chemo-attractant Proteins (MCP): CCL2, CCL7, CCL8 and 
CCL13. Serum levels of CCL2 (two-fold) and CCL3 (around five-fold) are significantly higher in DM 
patients than in healthy controls, while CCL4 levels are no different [12]. In IBM, mRNA expression 
of CCL3 and CCL4 is significantly upregulated versus controls (123- and 125-fold) and protein 
upregulation is confirmed by immunohistochemistry [22]. The Macrophage inflammatory proteins 
(MIP): CCL3 and CCL4, are produced by macrophages, DC and T-cells. A microarray study showed 
CCL4 and CCL13 upregulation in PM muscle, but not in DM [23]. Other chemokines attract mostly  
T-cells. The IFNγ-induced chemokines CXCL9–11 provide highly selective lymphocyte recruitment 
attracting subsets of CD4+ and CD8+ T-cells [24]. In addition to other chemokines, CXCL9 has been 
demonstrated to be highly upregulated and localized to muscle fibers in IBM, and this increase could 
contribute to infiltration of immune cells [22,25]. An important attractant for DC in particular is 
CXCL12. Pre-DC express the corresponding receptor CXCR4 and become highly motile in response 
to CXCL12 [26]. Mature DC, that have been shown to respond also to CCL2 and CCL20 [27], 
accumulate in muscle tissue from IIM patients. Increased levels of CXCL12 are associated with the 
IIM, and the primary sources of the chemokine inside the muscle tissue are inflammatory cells and 
blood vessels. In DM muscle, perimysial B-cells express varying levels of CXCL12 [28]. In addition, 
CXCL12 is chemotactic for pre- and pro-B-cells, but does not attract mature B-cells [29]. An 
important and more universal attractant for B-cells is CXCL13 or B-cell-attracting chemokine 1 [30], 
which is especially prominent in the larger perimysial infiltrates and the follicular structures within 
DM muscle [31]. 
2.3. Activation of Macrophages 
Functionally different macrophage lineages are present in IIM muscle: the classically activated  
pro-inflammatory M1 macrophages and the alternatively activated pro-tissue-repair M2 macrophages. 
The transformation of a circulating monocyte to classically activated M1 macrophages requires the 
exposure to two signals: priming by IFNγ followed by activation by TNFα directly or through an 
inducer of TNFα [32]. Both cytokines are expressed in IIM muscle. TNFα is a very prominent 
cytokine in IIM and high levels have been found both locally in the muscle as well as systemically in 
the serum of patients. TNFα levels were found eight-fold higher in DM/PM sera than in the sera of  
healthy controls [17]. In muscle lysates quantitative real-time PCR revealed that TNFα-mRNA was 
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upregulated in PM (26-fold) and DM (12-fold) and in IBM (53-fold) compared to controls [22].  
Both M1 and M2 macrophages are present in IIM muscle, and their relative proportions appear to be 
dynamic, altering with disease stage. M1 macrophages show increased inducible NO synthase activity, 
leading to an expanded capacity for producing cytotoxic NO. Tissue macrophages can organize into 
larger collections often surrounded by T-cells, forming an active and dynamic source of inflammatory 
cytokines that enhance each other’s activities. 
2.4. T-Cell Differentiation and Activation 
Clonal expansion of T-cells has been shown in PM/IBM muscle [33], indicating continuous  
antigen-driven immune reactions. Large numbers of CD4+ helper T-cells (Th) are present in IIM 
muscle. Differentiation into Th-subsets occurs through alternative activation of genes encoding 
transcription factors and cytokines, and suppression of genes associated with other lineages [34]. 
Many autoimmune diseases are dominated by Th1 immune-driven reactions, with prominent 
expression of the associated cytokines: IFNγ, IL-2, IL-12 and TNFα. IBM [35] as well as NAM [36] 
have been shown to display a prominent Th1 profile. IFNγ is three-fold increased in DM/PM patients, 
with even higher levels observed in IBM muscle [22]. IL-12 has been shown overexpressed in  
IBM [35], but others reported that IL-12 was not significantly altered in patients [17]. Expression of 
the chemokine receptor CXCR3 is associated with the Th1 lineage and DM/PM/IBM muscle contains 
high amounts of CXCR3+ CD4+ T-cells [37]. The receptor binds the IFNγ-inducible chemokines 
CXCL9, CXCL10 and CXCL11. CXCL9 has been shown to be upregulated in IBM [35] and PM, but 
not in DM samples [17]. CXCL10 serum levels have been found significantly increased in DM [12] 
and in DM/PM patients [17]. CXCL11 was found 5.5-fold (adult) and four-fold (juvenile) increased in 
DM sera, and protein levels correlated with disease activity [12]. Lower numbers of Th2 cells are 
found in IIM muscle. Cytokines mostly associated with the Th2 lineage are IL-4, IL-5, IL-6 and IL-13. 
IL-6 serum levels are significantly higher in DM than in control patients and correlate with disease 
activity [12]. 
IL-17 and the producing Th17 subset of CD4+ T-cells have been implicated in autoimmunity and 
are important pathogenic factors in rheumatoid arthritis and multiple sclerosis. Other Th17-associated 
cytokines are IL-21, IL-22, IL-23, IL-6 and TNF-related weak inducer of apoptosis (TWEAK). IL-17 
activates monocytes and innate immunity, and is increased in DM and PM [38,39]. A study in 31 IIM 
patients showed that IL-17 serum levels inversely correlated with manual muscle test scores. No such 
correlation could be shown for the other cytokines tested, i.e., IL-6, IL-10, IL-15, CCL2, CCL3 and 
CCL4 [16]. The Th17 pathway is important for maintaining chronic inflammation and is further 
regulated by cytokine expression. TWEAK stimulates IL-17 production by T-cells and favors Th17 
differentiation. Increased TWEAK expression has been observed in IBM muscle, but not in  
PM/DM [40]. In the presence of IL-12 and TNFα, Th17 cells can convert into alternative Th1-cells 
that secrete both IFNγ and IL-17 [41]. Furthermore, TWEAK has been proposed to impair muscle 
differentiation, linking inflammation with myogenesis. 
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2.5. Maturation of B-Cells into Plasma Cells 
Autoantibodies have been documented in DM, PM, IBM and NAM, and are increasingly 
recognized for their diagnostic potential. Antigen overexpression of known auto-antibodies has been 
noted in DM/PM [42]. Possibly, the enhanced tissue expression of these autoantigens, as part of  
the repair process in muscle, delivers them for recognition by autoantibodies, leading to ongoing 
autoimmune processes. Immunohistochemical staining showed the presence of fewer B-cells than 
differentiated plasma cells in IIM sections, with the plasma cells present in DM as well as in PM and 
IBM [43]. Interaction with T-cells in germinal centers of lymphoid structures have been shown to 
generate long-lived memory B-cells and effector plasma cells, and the lymphoid organizer LTβ is 
upregulated in CD20+ B-cells in DM tissues [44]. Clonal expansion suggests local and rapid  
transition of B-cells to antibody-producing plasma cells inside the muscle tissue. Local B-cell 
maturation in non-lymphoid tissues is a phenomenon observed also in other autoimmune diseases [45]. 
B-cell-activating factor (BAFF) is a crucial factor in the maintenance of B-cells, essential for the 
survival of mature B-cells. BAFF transcript has been reported to be markedly upregulated in DM  
(12-fold), PM (14-fold) and IBM (21-fold) compared to healthy samples [46]. BAFF expression by 
perimysial muscle fibers has been observed in DM [47]. Also, BAFF secreted by IFNα/β-stimulated  
DC activates B-cells and steers toward differentiation into (auto)antibody-producing plasma cells [48]. 
Different autoantibodies have been found associated with IIM subgroups. Anti-synthetase 
antibodies directed against cytoplasmic aminoacyl tRNA synthetases are the most prevalent. The  
anti-histidyl tRNA synthetase antibody termed Jo-1 is detected in 20% of DM/PM patients and is 
associated with a typical disease phenotype termed anti-synthetase syndrome [49]. With a lower 
frequency of ~5%, other antibodies are found, such as PL-7, PL-12, OJ, EJ, KS, Ha, and Zo, directed 
against different synthetases. Mi-2, directed against a component of the nucleosome remodeling 
deacetylase complex, is associated with a milder form of adult DM without interstitial lung disease or 
malignancy [50]. More severe IIM cases are associated with newly described auto-antibodies which 
mainly include enzymatic proteins i.e., TIF1-γ, NXP-2, MDA5 and SAE [51]. In NAM, anti-3-hydroxy-
3-methylglutaryl-coenzyme A reductase antibodies can be detected in statin-users [52]. Anti-signal 
recognition particle autoantibody (SRP) is associated with a rapidly progressive muscle weakness [53]. 
The muscle protein of 44 kDa (Mup44), which was identified as the cytosolic 5ʹ-nucleotidase 1A 
(cN1A) [54], represents a serological biomarker for systemic rheumatic disease and the IIM, including 
IBM [55]. These autoantibodies are referred to as myositis-specific and myositis-associated autoantibodies. 
3. Conventional and Established Therapies for IIM 
The therapeutic approach in myositis can be subdivided into initiating, maintenance and long-term 
therapy. For each treatment step, different immunosuppressive drugs are available. At the onset of 
disease, DM/PM/NAM are preferably treated with high-dose oral glucocorticosteroids (GC) or with 
intravenous methylprednisolone. In most patients GC are effective but the chance of relapses increases 
with tapering of the dose. Steroid-sparing drugs or second-line treatment such as azathioprine, 
methotrexate or intravenous immunoglobulins can be used for maintenance. Among the IIM, IBM is 
an exception as treatment has been shown mostly ineffective and remains controversial among experts. 
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3.1. General Treatment Recommendations for DM/PM/NAM 
The accepted initial standard treatment for these IIM subtypes are GC. An aggressive approach with 
high doses is recommended in severe conditions in form of pulsed intravenous GC application, e.g., 
250–500 mg prednisolone per day for 3–5 days. For milder clinical presentation and as a follow-up of 
the high-dose intravenous treatment, prednisone is given orally at 1 mg/kg bodyweight. The dosage is 
gradually reduced to a maintenance dose of 5–10 mg, to avoid disease relapses on the one hand, and 
adverse effects on the other hand. The most common adverse effects of GC treatment are edema, 
hypertension, potassium loss, insomnia, cataract/glaucoma and after long-term use osteoporosis, 
weight gain and steroid myopathy. The value of GC treatment in myositis has been described since 
1950 [56] but, although accepted in several guidelines, has never been proven in rigorous randomized 
controlled trials [57]. Lately, the alternative application of monthly treatment with high doses of 
dexamethasone was compared to daily doses of prednisolone in a multicenter, double-blinded study. 
The dexamethasone application was not superior in effectiveness to daily prednisolone as first-line 
treatment of myositis but in total showed less frequent side effects [58]. As far as patients respond to 
GC therapy, a long-term maintenance non-steroidal immunotherapy can be started in severe cases. One 
Cochrane-Review analyzing the therapies for DM/PM is available [59]. The authors identified 14 
relevant randomized-controlled trials (RCTs) from which four trials were excluded. The remaining  
10 RCTs comprised 258 patients following heterogeneous treatment regimens, showed association 
with various side effects. Due to the lack of high quality RCTs, the selection of immunosuppressants is 
mainly empirical and the choice is based on the risk-to-benefit ratio, costs and the local guidelines. 
In severe PM/DM/NAM, Azathioprine (AZA) can be given additionally to low dose prednisone. 
AZA is a purine antimetabolite that influences T- and B-cell proliferation. After testing the thiopurine 
methyltransferase (TPMT)-activity of the patient, the AZA therapy can be initiated with 50 mg/day 
and increased further under control of the blood count and liver enzymes to a target-dose of  
2–3 mg/kg/day. For an effective treatment, the number of lymphocytes should be 600–1000/µL. The 
therapeutic effect is usually not expected before three to six months. The safety profile of AZA is well 
known for several autoimmune diseases. At the beginning (after 10–14 days), in ~15% of patients  
an idiosyncratic reaction occurs which then requires stopping AZA treatment; the hepatotoxicity  
and leukopenia are reversible when detected early and AZA is discontinued or reduced. In case of  
long-term treatment, the potential risk of developing malignancies increases. One should always be 
aware of the life-threatening interaction with allopurinol. 
In case of AZA/prednisone failure or childbearing request, intravenous immunoglobulins (IVIG) 
can be tried as a second-line therapy. IVIG prepared from thousands of donors have numerous 
mechanisms of action including the interference with Fc receptors and Fc glycosylation, inhibition of 
cytokines and complement deposition or competition with autoantibodies [60]. The most convincing 
therapeutic effect was demonstrated for DM patients [61], but beneficial effects have also been shown 
in PM patients refractory to other treatments [62]. The initial dose is set to 2 g/kg, given either over 
five or two consecutive days. Due to its half-life of 18–32 days [63], maintenance dose of IVIG is 
infused regularly every four to eight weeks at a dose of 0.5–1 g/kg. In general, IVIG are well tolerated, 
but it is recommended that an IgA deficiency be ruled out before starting treatment. During the 
infusion, patients might complain of headache, chills, myalgia or chest complaints. Post infusion 
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fatigue, fever or nausea may occur. Caution should be given to thromboembolic or hemolytic events, 
aseptic meningitis or to patients with renal abnormalities. 
Methotrexate (MTX) is a folate inhibitor with a long immunosuppressive history for rheumatoid 
arthritis, and is therefore unfolding its effectiveness faster than AZA. MTX is a therapeutic option for 
severe PM/DM/NAM and in prednisolone refractory patients [64,65]. In addition, patients suffering 
from anti-synthetase syndrome with interstitial lung disease manifestations respond well to treatment 
with MTX [66]. Several doses and regimes have been described, but the most used application is an 
oral initial dose of 7.5 mg, although the subcutaneous application often shows more effectiveness  
and a better compatibility. After three weeks, MTX can be increased by 2.5 mg per week up to a total 
of 20–25 mg per week. MTX therapy should always be accompanied by an adequate folic acid 
supplementation. An important adverse effect is pneumonitis, sometimes difficult to distinguish from 
interstitial lung disease as seen in patients with Jo-1 positive anti-synthetase syndrome. Other side 
effects include hepatotoxicity, blood count alterations, gastrointestinal symptoms, renal abnormalities 
and malignancies. 
Cyclosporin and mycophenolatmofetil (MMF) are alternatives for severe or prednisone-refractory 
PM/DM/NAM [67]. Cyclosporin disrupts the calcineurin pathway inhibiting T-cell proliferation. As  
a therapeutic reserve in infantile DM, doses of 2.5 to 5 mg/kg per day divided in two daily doses  
are given depending on plasma-levels and effectiveness. In adults, 2–4 mg/kg per day are sufficient  
to maintain the immunosuppressive effect after an initial dose of four to six mg/kg per day. Overall,  
cyclosporin-use is uncommon in IIM due to severe side effects such as hypertension, nephrotoxicity 
and central nervous system neurotoxicity. MMF is a prodrug of mycophenolic acid and suppresses  
B- and T-cell proliferation through a selective block of purine synthesis [68]. Meanwhile, some case 
reports describe the successful treatment of prednisolone refractory myositis with MMF [69,70] by 
using a dose of 1000–2000 mg twice daily. Complete blood counts should be performed weekly during 
the first month and afterwards once or twice monthly. MMF offers some pharmacological advantages 
compared to other immunosuppressants, e.g., the metabolism is independent from the TPMT-activity 
and hepatotoxicity is less common compared to AZA. The main adverse drug reactions (≥1% of patients) 
associated with MMF therapy include gastrointestinal symptoms, joint pain, infections, hyperglycemia, 
hypercholesterolemia, leukopenia, and anemia and, more rarely, pulmonary fibrosis or various 
malignancies. Cases of progressive multifocal leukoencephalopathy (PML) have been reported, but a 
causal relationship for PML remains under debate [71]. As for other immunosuppressants, females of 
reproductive potential must be made aware of possible congenital malformations. 
In case of conventional treatment failure, cyclophosphamide is one of the strongest immunosuppressive 
drugs and has been used in DM/PM/NAM [72,73]. Cyclophosphamide is an alkylating agent of the 
nitrogen mustard group that must be processed in the liver to form the active aldophosphamide.  
Two ways of administration are available: 0.5–1.0 g/m2 can be given intravenously with an adequate 
co-medication, or 1–2 mg (cyclophosphamide)/kg/day orally. Its side effects include alopecia, bone 
marrow suppression, sterility, birth defects, mutations, and cancer. A strict monitoring of lymphocytes 
and neutrophils is necessary at day 7, 14 and 21. 
Biological agents offer another option for treatment escalation in myositis. The monoclonal 
antibody Rituximab (RTX) mediates a depletion of B-cells by targeting CD20. The efficacy of RTX 
has been tested in a randomized, double-blind, placebo-phase trial in adult and pediatric myositis 
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patients. An 83% success rate was achieved in a well-defined cohort of patients with treatment-refractory 
adult PM or adult or juvenile DM treated for 44 weeks [74,75]. Similar results were reported in  
a retrospective study of patients with severe, refractory PM or DM. The study demonstrated an 
objective improvement in the majority of patients with regard to creatine phosphokinase (CPK) and 
lung function tests [76]. These findings are supported by another retrospective study, which included 
24 RTX-treated anti-synthetase syndrome patients with severe interstitial lung disease, reporting an 
improvement of pulmonary function test after a median of 52 months follow-up post-RTX [77]. 
3.2. General Treatment Recommendations for IBM 
Although extensive research has been performed over the last years, debate is still ongoing as to 
whether IBM is primarily an inflammatory or a degenerative myopathy [78]. This has important 
implications, as a detailed understanding of disease pathomechanisms is crucial for the development of 
effective and specific drugs. A primary degenerative origin of IBM might explain the limited treatment 
efficacy of anti-inflammatory drugs. This assumption might be supported by a study that revealed  
that progression towards disability was exacerbated among patients receiving immunosuppressive  
drugs [79]. Although IBM was attributed with corticoid-resistance [80], individual patients have 
experienced a temporary clinical improvement under prednisolone therapy and no randomized studies 
to evaluate the steroid-efficacy have been conducted. Double-blinded studies that tested IVIG 
presented disappointing results. Authors concluded that treatment with IVIG may be either mildly 
effective on clinical outcome or even without any clinical relevance in IBM [81,82]. A significant 
effect of IVIG could however be achieved for the muscles of swallowing [62,83]. For MTX, a 
randomized, controlled study in 44 patients reported no improvement in muscle strength despite a 
significant decrease in creatine-kinase levels [84]. A combined therapeutical approach studied  
anti-T-lymphocyte globulin treatment followed by 12 months of oral MTX versus MTX alone in an 
open-label, randomized study. A slight improvement of distal upper extremity strength was noted for 
the combined therapy [85]. For MMF, a single case report with modest efficacy exists [86]. In a small 
study of 13 patients, alemtuzumab, a T-cell-depleting monoclonal antibody, was infused for four days 
with 0.3 mg/kg/d and showed to slow down the disease progression in some patients [87]. The 
promising results should be critically evaluated against possible severe side effects such as increased 
risk of opportunistic infection, autoimmune thyreoditis or idiopathic thrombocytopenic purpura. 
Taking the evidence together, no overall effective treatment is available today for IBM and according 
to the immunuosuppressive associated side-effects, most experts even abandon this option. At the 
moment, expectations rest upon an anti-myostatin approach that uses the humanized monoclonal 
antibody Bimagrumab [88]. This pilot trial, in which 11 patients received a single dose of bimagrumab 
and three received placebo, reported increased muscle mass after eight weeks and an improved  
six-minute walking distance after 16 weeks of dosing. Based upon these promising data, a large 
multicentre randomized, double blind, placebo-controlled study was initiated in 2013. The recruitment 
of 240 patients has been completed and the last infusion will be administered by the end of this year 
(the RESILIENT trial; NCT01925209). So far, the benefit remains unknown and the results on 
efficacy and safety are awaited by the myositis community. 
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4. Anti-Cytokine Agents and Their Potential for Treating IIM 
Over the years, a more detailed understanding of the inflammatory process and the molecular 
pathways involved could provide alternative options for long-treatment resistant cases. A major approach 
for the development of targeted therapeutics for IIM has been attributed to cytokine-networks. The  
pro-inflammatory cytokines activated in the IIM offer attractive therapeutic targets. Cytokine-targeted 
therapies can be based upon (I) inhibition of cytokine production; (II) inhibition of cytokine action;  
(III) blockade of cytokine function; or (IV) receptor targeted therapy. These approaches necessitate  
the full evaluation of the repercussions of eliminating individual or several cytokines upon tissues.  
A thorough evaluation of the reduction/modification of cytokine patterns in inflammatory disease 
models, and the possible beneficial effects on health, could provide an excellent basis for designing 
therapeutic strategies for the future. 
An inhibitor of cytokine gene transcription is thalidomide, which has multiple cellular and 
molecular effects [89] e.g., exhibiting anti-inflammatory and immunomodulatory properties [90].  
One key mechanism is the destruction of TNFα mRNA [91]. In addition, the production of the 
proinflammatory cytokines IL-1, IL-6 and IL-12 from human mononuclear cells is blocked [92]. 
Originally, thalidomide was sold as a sedative and hypnotic drug but was withdrawn due to 
teratogenicity and neuropathy after several years [93]. Later, thalidomide had a revival as a drug 
against refractory multiple myeloma [94]. A few case reports describing the efficacy of thalidomide in 
patients with refractory IIM have been reported [95,96]. The teratogenic potential is aimed to be 
overcome by analogues of thalidomide such as lenalidomide with an even greater potency in inhibiting 
TNF production [97]. To date however clinical trials with thalidomide or lenalidomide have not  
been started. 
One of the most sought-after approaches for reducing cytokine activity is to develop drugs that 
specifically bind and neutralize an individual cytokine, or the receptor it activates. This can be 
achieved by administering small-molecule antagonists of receptors, modified cytokines, or antibodies 
directed against cytokines or their receptors. Monoclonal antibodies are convenient therapeutic agents, 
not in the least by their excellent specificity, yet they come with important technical challenges. One of 
the most important is that they can elicit immunogenic responses in the patient. To circumvent this 
issue, engineered antibody constructs are continuously being developed. Starting from mouse 
antibodies, murine constant regions are replaced by human constant regions, creating chimeric 
antibodies. When all regions except the complementarity determining regions of the variable regions 
are of mouse-sequence origin, antibodies become humanized and ultimately fully human antibodies are 
created. Nonetheless, fully human sequence derived antibodies are, of course, less immunogenic, but 
can still induce immune responses. In rheumatoid arthritis, patients co-medicated with MTX and 
Golimumab, for instance, 16% were shown to have anti-drug antibodies [98]. 
Most important anti-cytokines agents, evidenced in patients with inflammatory disease and, when 
available, results from case reports and clinical trials in IIM (Table 1) [99–118] are listed hereunder. 
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Table 1. Results reported for anti-cytokine agents in refractory idiopathic inflammatory myopathies. 





Clinical Outcome Reference 
Anti-TNFα     
infliximab 6 mg/kg 4-weekly or more frequent jDM/5 32 to 130 I (5/5) [99] 
infliximab 10 mg/kg (week 0, 2, 6, 14) 
DM/1 
16 I (3/9); NC (4/9);W (2/9) [100] PM/4 
IBM/4 
infliximab 10 mg/kg (week 0, 2, 4) 
DM/1 
12 I (2/2) [101] 
PM/1 
infliximab 10 mg/kg (week 20) DM/1 
66 I (2/2) [102] 
infliximab 10 mg/kg (week 14, 18, 22) PM/1 
infliximab 10 mg/kg (week 0, 2, 6, 14, 22) PM/2 26 I (2/2) [103] 
infliximab 10 mg/kg (week 0, 2, 4, 6, 9) PM/1 69 I (1/1) [104] 
infliximab 5 mg/kg (week 0, 2, 6, 14, 18, 22) PM/1 22 I (1/1) [105] 
infliximab 5 mg/kg weekly (0, 2, 6) every 8 weeks DM + ILD/14  I (10/14); † (4/10) [106] 
infliximab 3 mg/kg (week 0, 2, 6,every 8)  
and or etanercept 25 mg twice weekly 
DM/3 
26 I (6/8) [107] 
PM/5 
etanercept 50 mg weekly for 24 weeks 
DM/8 
24 I (6/11); NC (3/11); W (2/11) [108] 
DM/3 
etanercept 25 mg twice weekly PM/1 56 I (1/1) [109] 
etanercept 25 mg twice weekly IBM/9 24 to 48 I [110] 
etanercept 25 mg twice weekly DM/5 12 W (5/5) [111] 
etanercept 0.4 mg/kg twice weekly 1–12, 13–24 stop jDM/6 12 I (3/6); NC (1/6); W (2/6) [112] 
Anti-IFNα     
sifalimumab  
0.3–10 mg/kg every other week, 6 months 
DM/26 
14 I (38/51) [113] 
PM/25 
avonex (βIFN1a)  
30 µg weekly, 6 months 
IBM/29 24 NC (27/29); W (2/29) [114] 
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Table 1. Cont. 





Clinical Outcome Reference 
Anti-IL-1     
anakinra 100 mg daily 
PM/6 
48 I (7/15); NC (5/15); W (3/15) [115] DM/4 
IBM/5 
anakinra 100 mg daily IBM/4 28 W (4/4) [116] 





80 I (1/1) [117] 
Anti-IL-6 
tocilizumab 8 mg/kg every 4 weeks PM/2 29 to 43 I (2/2) [118] 
Abbreviations: (juvenile) dermatomyositis ((j)DM), improved (I), sporadic inclusion body myositis (IBM), no change (NC), polymyositis (PM), DM/PM/IBM 
(DM/PM/IBM), worsened (W). Number of patients (#Patients), deceased (†). 
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4.1. Targeting TNFα 
The important catabolic role of TNFα as a regulator of various chronic inflammatory diseases has 
made it a therapeutic target also in the IIM. Fortunately, murine studies showed that knocking out 
TNFα does not hamper skeletal muscle regeneration [119]. The cellular sources of TNFα in IIM are 
mostly the inflammatory cells, endomysial and perimysial mononuclear cells in DM/PM muscle 
samples express varying amounts of TNFα [120]. In DM, TNFα is also expressed by many endothelial 
cells and its soluble receptors TNF-R55 and TNF-R75 are increased in DM/PM serum compared to 
controls [121]. TNF-R75 is notably increased near inflammatory infiltrates in muscle from all IIM 
patient groups, and on the perimysial and perifascicular blood vessel endothelium in DM, even remote 
from inflammation [122]. 
In a strategy to inhibit posttranslational processing of TNFα, TNFα converting enzyme 
(TACE/ADAM17/CD156q) comes into the light. TACE is a multi-domain, transmembrane  
protein [123] that generates soluble forms of TNFα and other proteins from their membrane-bound 
precursors through a process that cleaves and releases the soluble ectodomain [124]. TACE inhibitors 
have been designed for treating rheumatoid arthritis, and have been tested in animal models and in 
clinical trials [125]. The initial promising TMI-005 (Apratastat) showed no hepatotoxicity, but the 
efficacy results prompted the company to terminate the trial [126]. As future treatment strategies, 
specific TACE inhibitors, which block formation of soluble TNF, are still awaited [127]. 
Many therapeutic anti-TNFα antibodies have been developed. Infliximab (Remicade), Adalimumab 
(Humira) and Golimumab (Simponi) are humanized monoclonal anti-TNF antibodies. Nerelimomab 
(Norasept) is a chimeric anti-TNFα monoclonal antibody. Certolizumab pegol is a PEGylated  
Fabʹ-fragment of a humanized antibody. Etanercept (Enbrel) is a fusion protein of TNFR2 bound to  
Fc-fragment of IgG1. Rheumatoid arthritis patients are being treated successfully with anti-TNFα 
agents for many years now [128]. In the IIM, several phase II clinical trials have been started up but, in 
general, studies suffer from low inclusion numbers and notably high drop-out rates mostly due to 
disease deterioration and adverse events (Table 1) [99–112]. However, it appears that anti-TNFα 
treatment could be of benefit to a subset of IIM patients. The identification of responsive patients 
remains difficult, as no specific marker has been identified yet that may predict the therapeutic 
outcome. Also, DM, PM and anti-synthetase syndrome have emerged in patients with other chronic 
inflammatory diseases for which they were taking anti-TNFα agents [129]. 
4.2. Targeting IFNα/β 
An impressive IFN type 1-induced gene repertory is activated in DM, and milder upregulation of 
these genes is also observed in PM and IBM. Among the induced pathogenic gene products are major 
histocompatibility complexes, myxovirus resistance proteins, RNA helicases and cytokines [130].  
Anti-IFN type 1 therapy would be able to calm down innate immunity-related reactions, neutralizing 
the IFN type 1-stimulated gene expression. 
The immunomodulatory cytokine βINF counteracts the immunostimulatory effects of IFNγ and 
inhibits lymphocyte migration: this feature makes it a candidate therapeutic agent. The compound 
βINF1a (Avonex) has been tried in IBM and showed no significant effect on muscle strength [114]. 
Int. J. Mol. Sci. 2015, 16 18696 
 
 
Human anti-IFNα R monoclonal antibody MEDI-546 has been found safe in a Phase I trial with 
systemic sclerosis patients [131]. 
Several anti-IFNα antibodies have been developed. Sifalimumab, Rontalizumab and AGS-009 are 
monoclonal anti-IFNα antibodies. Results of a first Phase Ib clinical trial in IIM have been published. 
Six-months treatment with Sifalimumab suppressed the IFN type 1 gene signature in a cohort of  
DM and PM patients, including downregulation of IL-18 expression. Patient’s improvement of muscle 
strength correlated with greater neutralization of the type 1 IFN signature in blood and muscle [113].  
In muscle biopsies from two selected treated patients, decreased T-cell infiltration was observed [114]. 
Blood analyses showed that five out of the 11 suppressed serum proteins were IFN-inducible, being 
sIL2R, CCL2, CCL8, BAFF and Ferritin, and that treatment reduced CXCL10 immunoreactivity in 
muscle from a PM patient. The medical community awaits results from other trials with great interest. 
4.3. Targeting IFNγ 
Unequivocal results have been published on IFNγ expression in the IIM [130], and several aspects 
of the specific role of IFNγ in the immunopathogenesis of the IIM remain elusive today. However, it 
seems its cross-talk with type 1 IFN could be an important aspect. In synergy with IFNα/β, IFNγ  
can shift immune responses toward Th1-mediated reactions, which, in turn, further perpetuate  
IFNγ production. 
The humanized anti-IFNγ antibody Fontolizumab (HuZAF) has been developed, and has been 
shown efficacious for treating inflammatory bowel disease [132]. No results for treating IIM have  
been published. 
4.4. Targeting BAFF 
Of the TNF-family of cytokines other than TNFα, BAFF comes forward as an amenable target for 
treating the IIM [133]. Circulating BAFF levels have been found elevated in many patients with 
autoimmune diseases and, as a vital B-cell survival factor, it has emerged as a logical therapeutic target 
for combating B-cell hyperactivity. Targeting B-cells indirectly, rather than by a direct CD20-based 
approach (RTX) that has also been developed, has substantial advantages. Autoreactive B-cells tend to 
have a greater dependency on BAFF for their survival [134], which means that pathogenic B-cells 
could preferentially be eliminated this way. Non-selective B-cell depletion also risks harm to the 
protective capacities of the subset of regulatory B-cells [135]. In addition, BAFF influences T-cell 
function, more particular stimulating the Th1 [136] and Th17 [137] lineages. Targeting BAFF may 
thus counter both pathogenic B-cells and pathogenic T-cells in autoimmune diseases. BAFF has three 
receptors on B cells: B-cell maturation antigen (BCMA), TNFR homolog transmembrane activator and 
Ca2+ modulator and CAML interactor (TACI), and BAFF receptor (BR3). BCMA and TACI bind 
BAFF and the related cytokine a proliferation inducing ligand (APRIL). As APRIL contributes to the 
survival of plasma cells [138], blocking these receptors can neutralize both cytokines simultaneously, 
which may lead to an added neutralizing effect on auto-antibody production. 
Several anti-BAFF agents have been developed. Fully human Belimumab (Benlysta, LymphoStat-B) 
and Tabalumab are monoclonal anti-BAFF antibodies. Blisbimod (AMG623) is a so-called peptibody 
i.e., a fusion protein between IgG Fc and a BAFF-binding peptide sequence. Atacicept (TACI-Ig) is a 
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receptor-Fc fusion protein that neutralizes both BAFF and APRIL signaling. Briobacept (BR3-Fc) is a 
fusion protein between BR3 and IgG Fc. Belimumab has been approved for treating systemic lupus 
erythematosus, where it has been shown to be safe and efficient for reducing peripheral blood B-cell 
numbers and circulating anti-dsDNA antibody levels [139]. Atacicept has also been shown to 
ameliorate systemic lupus erythematosus disease severity [140]. In a group of patients with acute 
rheumatoid arthritis, stable on MTX but with no adequate response to TNF inhibitors, Tabalumab 
showed indications of efficacy [141]. No trials have been started up with IIM patients so far. 
4.5. Targeting IL-1 
IL-1 is a crucial mediator of the inflammatory responses in chronic inflammatory conditions, and 
mediates muscle fiber damage in the IIM. In IIM muscle, IL-1 is mainly produced by activated 
macrophages, endothelial cells and muscle fibers [120,142,143]. IL-1α serum levels are increased in 
DM/PM patients, and correlates with disease activity [144,145]. The balance between IL-1 and its 
soluble receptor antagonist (IL-1Ra) is strictly regulated and imbalance between the two has been put 
forward as a disease aggravating factor [146]. IL-1 receptor antagonist (IL-1Ra) expression was shown 
to be increased in DM/PM sera [121], pointing to a regulatory function. 
The IL-1β converting enzyme inhibitor Pralnacasan had already been tested in Phase IIb clinical 
trial on rheumatoid arthritis when results from an animal toxicology study showed liver abnormalities 
after a nine-month exposure at high doses. The trial was voluntarily discontinued. 
Two receptor antagonists that block the effects of both IL-1α and IL-1β, have been developed. 
Anakinra (Kineret) is a recombinant soluble receptor IL-1Ra. Rilonacept is a dimer of IL-1R1 and  
IL-1RAcP linked to Fc-fragment of IgG1. The compounds Canakinumab and Gevokizumab are 
monoclonal anti-IL-1β antibodies. Anakinra has been tried in IIM and showed a response in some of 
the patients (Table 1) [115–117]. In a patient with familial Mediterranean fever and spondyloarthritis, 
subsequent myositis was successfully treated with Anakinra [147]. Gevokizumab is currently being 
tested in a randomized, double blind, placebo-controlled proof of concept study in patients with 
PM/DM/NAM (Integrated Research Approval System number 135286, European Union Drug 
Regulating Authorities Clinical Trials number 2012-005772-34). 
4.6. Targeting IL-2 
IL-2 expression, which is significantly increased in DM/PM sera [17], has been implicated in 
inflammatory diseases, activating T-cells as well as B-cells. A case report describes the development of 
myositis with endomysial inflammation in a patient treated with high dose IL-2 [148], illustrating  
the cytokine’s pro-inflammatory power. This patient received IL-2 for treating his advanced renal  
cell cancer, following the FDA approval that was issued due to the associated tumor regression and  
favorable outcome. 
Chimeric Basiliximab and humanized Daclizumab are therapeutic monoclonal anti-IL-2Ralpha 
chain (CD25) antibodies. Daclizumab has been tested in several Phase II clinical trials for treating 
multiple sclerosis [149] and inflammatory bowel disease [150]. No results have been published in  
IIM patients. 
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4.7. Targeting IL-6 
IL-6 is a cytokine with both pro- and anti-inflammatory properties. Classical IL-6 signaling 
mediates the activation of anti-inflammatory and regenerative pathways and is accomplished via the  
membrane-bound IL-6R. After binding IL-6, membrane-bound IL-6R recruits the signal-transducing 
receptor glycoprotein 130 kDa (gp130) [151]. Agonistic interaction with the soluble non-signal-transducing 
IL-6R on the other hand, can also occur. The IL-6/soluble IL-6R complex binds to a homodimer of 
gp130 on the cell surface, leading to so-called trans-signaling [152]. Trans-signaling activates a  
pro-inflammatory program. Immune cell recruitment is stimulated through induction of adhesion 
molecules and CCL2 expression by endothelial cells [153]. As most cell types, endothelial cells do not 
posses membrane-bound IL-6R, making them unresponsive to classical IL-6 signaling [154]. Healthy 
individuals have low levels of circulating IL-6 and higher levels of soluble IL-6R and gp130. Both  
IL-6 and soluble IL-6R are commonly upregulated in patients and autoimmune diseases, which are 
driven by IL-6 trans-signaling rather than classic signaling [155]. IL-6 serum levels are increased in 
DM and correlate with disease activity [12]. 
An impressive number of IL-6 targeting therapeutic antibodies have been developed. Tocilizumab, 
Sarilumab, Atlizumab (Actemra) and Sirukumab are therapeutic monoclonal anti-IL-6R antibodies. 
Olokizumab, Clazakizumab, Elsilimomab and Siltuximab are monoclonal anti-IL6 antibodies.  
BMS-945429 (ALD518) is an aglycosylated humanized monoclonal anti-IL-6 antibody. The Sgp130Fc 
agent is composed of the extracellular domain of human gp130 bound to the Fc-fragment of  
IgG1. While anti-IL-6 and IL-6R antibodies may not discriminate between signals initiated by  
membrane-bound or soluble receptors, Sgp130Fc selectively blocks IL-6 trans-signaling without affecting 
classic signaling [156]. 
One report describes successful Tocilizumab treatment in two patients with refractory PM  
(Table 1) [118]. Another report describes a patient with overlap syndrome that has been successfully 
treated recently [157]. In inflammatory bowel disease, Tocilizumab has also been shown to create 
clinical benefit [158]. In rheumatoid arthritis patients, administering Tocilizumab caused a shift in  
B-cell properties toward regulatory activities [159]. A Phase II trial with Tocilizumab for treating 
refractory DM and PM has been started (NCT02043548). 
4.8. Targeting IL-12/IL-23 
IL-12 is a heterodimeric cytokine composed of p35 and p40 subunits that stimulates Th1-cells. The 
related IL-23 is a heterodimeric Th17-associated cytokine that consist of p19 and p40 subunits, the 
latter it shares with IL-12. A role for IL-12 in myogenic differentiation has been reported [160], and 
the cytokine is overexpressed in IBM blood and muscle [35]. 
Ustekinumab and Briakinumab (ABT-874) are monoclonal anti-IL-12/IL-23 p40 subunit antibodies. 
Guselkumab and Tildrakizumab are therapeutic anti-IL-23 antibodies. Ustekinumab and Briakinumab 
are effective in psoriasis [161–163] and reduce both Th17 and Th1 cell numbers. Ustekinumab has 
also been tried in Crohn’s disease [164] and multiple sclerosis [165]. 
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4.9. Targeting IL-17 
The six IL-17 subforms A to F are pro-inflammatory cytokines, and their key source, i.e., the  
Th17-cells, are abundant in inflammatory disease. IL-17 activates pro-inflammatory transcription 
factors, inducing cytokines, growth factors and other inflammatory mediators. Increased expression 
has also been shown in IIM muscle and serum [38]. 
Several therapeutic anti-IL17 antibodies have been developed, of which most are directed against 
the IL-17A form. Brodalumab, Secukinumab and AMG-827 are fully human monoclonal anti-IL17 
antibodies. Ixekizumab, Perakizumab and LY2439821 are humanized monoclonal anti-IL17 antibodies. 
Secukinumab, Ixekizumab and Brodalumab have been evaluated in phase II clinical trials for 
rheumatoid arthritis [166], and phase III trials are ongoing. Their efficacy has been shown in psoriasis 
patients [167–169]. No results have been published in IIM patients. 
4.10. Targeting CXCL10 
The prominence of the CXCL10/CXCR3 axis in the IIM makes it an amenable target for therapeutic 
intervention. Our own results [37], since corroborated by others, have shown strong expression of 
CXCL10 and important infiltration by CXCR3+ cells in DM, PM as well as IBM. Inflammatory 
challenge has been shown to induce CXCL10 expression in myoblast cultures [170,171]. Vitamin D 
receptor agonists have been shown to counteract CXCL10 secretion by stimulated cells in vitro and 
their use as therapeutic agents in the IIM has been put forward [172]. 
Human monoclonal anti-CXCL10 antibodies have been developed and include MDX-1100 and  
BMS-936557. A Phase II double blind randomized study in patients with active ulcerative colitis  
showed improved clinical and histological parameters following eight weeks of BMS-936557  
therapy [173]. A Phase II study of MDX-1100 and MTX combined for treating active rheumatoid 
arthritis has been completed and awaits publication of results (NTC01017367). To our knowledge, no 
trials for treating IIM have been started. 
4.11. Targeting CCL2 
CCL2 is prominently expressed in IIM, where it localizes to blood vessels and inflammatory cells. 
In PM and IBM, the macrophages and T-cells actively invading nonnecrotic muscle fibers express 
remarkably high levels of the chemokine [174]. The CCL2 expression profile points to an important 
role in myocytotoxicity directed against the muscle fibers in PM/IBM, as well as to a role in the 
endotheliopathy associated with DM, and makes it an amenable target for treating different IIM subgroups. 
The development of anti-CCL2 therapeutics is currently at an early stage. A human monoclonal 
antibody against CCL2 termed Carlumab, and a humanized monoclonal antibody with high specificity 
to CCR2 termed MLN1202 have been generated. Carlumab is currently studied as an anti-cancer agent 
but has, to our knowledge, not yet been tested in inflammatory disease. A Phase IIa clinical trial with 
MLN1202 for treating rheumatoid arthritis showed no amelioration of synovial inflammation in active 
disease [175]. A proof of mechanism study will be started to assess if synovial inflammation can be 
reduced by the compound in atherosclerotic cardiovascular disease (NCT02388971). 
  




There is a lack of consensus on standard care in IIM and no universal treatment recommendations 
have been put forward as yet. The use of GC remains the cornerstone of treatment, but the therapeutic 
armamentarium is in need of expansion, as no suitable therapy can be offered to large numbers  
of IIM patients. Also, therapy should be shaped to avoid recurrent infections and development of 
malignancies, as the approach most often requires lifelong treatment. The medical community awaits 
the reduction of risks associated with more specific immunosuppression. In this respect, cytokine-based 
treatment could offer the possibility of regulating the magnitude and duration of the immune response 
by restoring the regulatory immune balance. 
Conventional immunosuppressive therapy reduces the expression of cytokines in responsive IIM 
patients. GC can act via the activated GC-receptor complex, which translocates as a dimer to the 
nucleus and activates the GC responsive element on GC-responsive genes with a subsequent increase 
of genes coding for anti-inflammatory proteins [176]. An additional mechanism is the suppression of 
the expression of responsive pro-inflammatory genes [177]. GC are able to strongly diminish the 
production of the “initial phase” cytokines IL-1β and TNFα and the “immunomodulatory” cytokines 
IL-2, IL-3, IL-4, IL-5, IL-10, IL-12 and IFNγ, as well as of IL-6, IL-8 and the growth factor  
GM-CSF [178]. Indiscriminate inhibition of the production of the “anti-inflammatory” cytokines, such 
as IL-10, might be responsible for treatment failures in myositis. 
As they represent a relatively rare group of disorders, reports on the efficacy of anti-cytokine 
therapy in clinical trials enrolling IIM patients remain sparse. Interpretation of the results is not only 
difficult due to the small size of cohorts, but also due to the heterogeneity of the studied population. 
Beneficial effects have been reported for anti-TNFα, IFNα/β, IL-1 and IL-6 strategies in some of the 
patients, but it seems unlikely that in a heterogeneous and complex group of diseases, as is the case 
with IIM, targeting a single cytokine would lead to a meaningful amelioration of disease in every 
single case. Undoubtedly, the complexity of IIM subgroup-specific immunopathogenic mechanisms 
will necessitate further subtyping of patients, in order to predict therapeutic outcome, evolving to a 
more personalized therapeutic approach. It should also be taken into account that non-immune 
mechanisms can be equally crucial events in IIM pathology. In this respect, discussion on the  
primary degenerative or inflammatory origin of IBM is of interest. Also, in some of the patients, 
immunosuppression leads to complete removal of inflammation, yet without any clinical improvement. 
Also, the degree of inflammation does not always correlate with severity of muscle dysfunction. In 
IBM patients IVIG and/or prednisone treatment did not improve their muscle complaints. In these 
patients, muscle IL-1β, IFNγ, CXCL9, CCL3, CCL4 and TGFβ messenger levels were reduced, but 
TNFα and IL-6 levels were unaffected by the therapy [179]. From these results, one can conclude that 
reductions of individual cytokines do not necessarily predict therapeutic response, and that certain 
cytokines might be pathogenically more powerful and more difficult to neutralize. 
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